Professor Wong’s research introduces a pioneering concept termed “differential communication,” which uncovers how companies craft bilingual disclosures with intentional disparities. This subtle yet impactful stratagem is designed to provide local investors with richer, more insightful information than their foreign counterparts. The study, recently published in The Accounting Review, employs innovative machine learning techniques to expose these crafted informational inequalities, fundamentally altering our understanding of investor relations in multinational markets.

The catalyst for this research was a seemingly mundane encounter: Professor Wong observed notable translation discrepancies in the Chinese and English versions of a retail store’s return policy. Intrigued by this inconsistency, he hypothesized that similar tactics could be employed in corporate disclosures, potentially skewing information availability. This insight spurred a rigorous investigation into how companies translate— and more importantly, selectively transform—their financial narratives across languages.

Historically, detecting such strategic disparities was elusive. Companies’ biased communication often transpired in private, off-the-record conversations or internal emails, places inaccessible to outsiders and regulators alike. To overcome this opacity, Professor Wong and his team adopted an innovative approach—directly comparing the Chinese and English versions of the same annual reports. This direct comparison sidesteps the conventional practice of translating documents into a third “pivot” language, which typically introduces noise and reduces analytical precision.

The team developed a state-of-the-art joint-language machine learning model complemented by an AI methodology that can differentiate substantive translation gaps from trivial stylistic variances. By filtering out superficial differences, this technology isolates discrepancies with material significance to firm performance. This nuanced approach ensures that only politically and economically consequential disparities are identified, advancing beyond earlier, cruder methods.

One of the most remarkable aspects of this breakthrough is its generalizability. Since it operates without an intermediate translation step, this methodology can detect hidden divergences in any bilingual or multilingual high-stakes environment. Legal treaties, government contracts, and other official documents stand to benefit from this technology, enabling stakeholders to root out covert informational asymmetries and enforce greater transparency.

The research reveals that these discrepancies, termed “translation gaps,” are not offhand mistakes or translation errors but deliberate, systematic strategies. When a company’s English report conveys markedly different information from its Chinese counterpart, it fuels increased information asymmetry. This imbalance profoundly affects market fairness, with foreign investors routinely receiving lower-quality disclosures, which in turn hampers their ability to produce accurate financial forecasts.

Moreover, this strategic withholding is not limited to casual information but focuses on complex, relationship-based content intrinsic to local market knowledge. Companies emphasize straightforward accounting details in English to cater to foreign investors’ specific governance concerns but obscure nuanced insights that local investors naturally access. This dynamic deepens the structural disadvantage embedded within the global financial ecosystem.

To validate these findings, Professor Wong’s team undertook a bold field experiment, posing as investors engaging directly with companies. The results were unequivocal: firms exhibiting larger translation gaps were significantly less responsive to inquiries from foreign investor personas. This deliberate reluctance to engage highlights an intentional strategy aimed at maintaining informational barriers rather than simple oversight or incompetence.

This body of research has immediate and significant implications for global regulators. While cutting-edge AI tools can bring hidden translation biases to light, they cannot by themselves enforce equitable disclosure practices. Without regulatory mandates requiring companies to provide identical information across languages, these translation gaps persist, benefiting domestic stakeholders at the cost of international market fairness.

Professor Wong’s extensive experience in market supervision bolsters the policy relevance of this work. His prior studies have informed pivotal rulings by the United States Securities and Exchange Commission (SEC), including the 2023 Final Rule on Modernization of Beneficial Ownership Reporting and the 2024 Final Rule concerning Short Position and Short Activity Reporting. His expertise has also contributed to addressing climate-related data gaps, notably cited by Deutsche Bundesbank.

Supported by prestigious programs such as the Google Cloud Research Credits, this research merges advanced technological innovation with profound regulatory insight. It surfaces critical evidence showing that, despite technological progress, bridging global equity markets’ informational divides ultimately hinges on regulatory intervention. Such reforms are vital to preserving market integrity and ensuring that foreign capital can compete on a genuinely level playing field.

As financial globalization advances, the findings from this study underscore the urgency of transparency reforms. Investors, regulators, and academics alike must recognize that language and culture are not mere barriers but tools wielded strategically within corporate communication. Unlocking truly global finance requires dismantling these engineered informational silos, using both technology and policy to uphold equity across borders.

Subject of Research:
Article Title: Lost in translation: CityUHK research unveils hidden “home court advantages” in the market
News Publication Date: 25-Mar-2026
Web References: http://dx.doi.org/10.2308/TAR-2023-0274
Image Credits: City University of Hong Kong
Keywords: Economics, Business, Information Asymmetry, Translation Gaps, Machine Learning, Artificial Intelligence, Financial Disclosure, Corporate Communication, Regulatory Policy, Investor Relations

The burgeoning demand for advanced lithium-ion battery technology is driven by the unprecedented growth in the global EV market and renewable energy sector. Recognizing the critical importance of cathode materials in battery performance, the research team at CityUHK aims to tackle the long-standing issue of voltage decay that has historically plagued lithium-rich cathode materials. This problem not only impedes the commercial viability of LLOs but also limits their full potential in enhancing battery performance.

Funded under the “RAISe+ Scheme” by the Hong Kong Special Administrative Region of the People’s Republic of China, the project is ambitiously titled “Breakthrough Cathode Materials for Next-generation Lithium-ion Batteries.” The research initiative’s goal is to pioneer and optimize a new range of battery materials that promise enhanced energy density, extended lifespan, and reduced manufacturing costs. This innovation is expected to create a ripple effect, generating approximately 100 new jobs as the team constructs a 1,000-ton materials production line.

At the heart of this transformative research lies the stabilization of the honeycomb structure inherent in LLOs. By integrating additional transition metal (TM) ions into the cathode material, the research team aims to inhibit common failures such as oxygen release, cation migration, and structural degradation. This strategic modification directly addresses the voltage decay that poses a formidable challenge to the performance of lithium-rich cathode materials, allowing for a new era of high-performance LLOs.

In addition to addressing voltage decay, the team utilizes state-of-the-art surface engineering techniques to combat capacity decay induced by surface degradation, TM ion dissolution, and the corrosive effects of electrolytes. One noteworthy approach involves the application of carbon coating layers during the calcination process, which forms a protective barrier around the cathode material. This innovation not only contributes to the longevity of the battery but also represents a significant leap forward in energy storage technology.

The ambitious effort by CityUHK’s research team has resulted in groundbreaking findings that were published in the prestigious journal Nature Energy in 2023. These advancements lay the groundwork for two targeted product lines: one focused on enhancing the energy density of traditional lithium-ion batteries by over 30% while reducing costs, and the other aimed at developing LLOs specifically for solid-state batteries. This multifaceted approach emphasizes the versatility and applicability of their research, showcasing the potential to revolutionize the energy storage sector.

What makes this research particularly compelling is its alignment with global efforts to combat climate change and transition to cleaner energy sources. As the market for lithium-ion batteries is projected to soar to an astounding US$150 billion by 2030, with the cathode materials sector anticipated to contribute over US$60 billion to that figure, the implications of this research echo far beyond the laboratory. With more efficient and cost-effective batteries, the potential for widespread adoption of EVs and renewable energy systems becomes increasingly plausible.

Professor Liu’s assertion that the research team’s work allows LLOs to fulfill their commercial potential cannot be overlooked. The translated technology promises batteries that not only deliver higher energy density at reduced costs but also enable new applications in both the EV sector and energy storage solutions. This initiative not only reinforces Hong Kong’s position as a hub for cutting-edge energy technologies but also enhances its footprint within the global high-tech landscape.

The establishment of SuFang New Energy Technology Co., Ltd. marks another milestone in this project. With an initial production line boasting an annual capacity of 100 tons dedicated to the industrialization of LLOs, this move signifies a commitment to scaling up production to meet growing market demands. The plan to further develop a 1,000-ton materials production line in Southeast Asia or Korea is rooted in the aim of establishing a robust supply chain capable of supporting the burgeoning demand for advanced battery materials.

Looking ahead, the collaboration with RAISe+ Scheme propels the project into a new phase of development, aiming for an operational 1,000-ton production capacity within the next three years. This ambitious initiative is poised to create significant opportunities within Hong Kong’s research, manufacturing, and engineering sectors. The projection of generating approximately 100 new jobs not only highlights the economic potential of this project but also underscores its societal impact as it prepares to transition into an industrial-scale operation.

As society leans more heavily on electric power and renewable energy, the importance of advancing battery technology cannot be understated. The breakthroughs facilitated by CityUHK’s research team position them at the forefront of this global shift, providing a template for future developments in battery technology. Through innovative research and strategic partnerships, they are well-positioned to make profound contributions to the field, ensuring batteries not only meet but exceed the expectations of consumers and industries alike.

This research represents an exciting convergence of applied science and technology that promises to reshape energy storage solutions for generations to come. As lithium-ion batteries become increasingly integral to our daily lives, the initiatives taken by researchers like Professor Liu and his team emphasize the critical importance of science, innovation, and industrial collaboration in driving the global energy transition forward.

In conclusion, the trajectory of this project not only underscores the essential role of advanced lithium-ion batteries in modern energy paradigms but also epitomizes the innovative spirit of researchers dedicated to discovering solutions to some of the most pressing challenges facing our world today. The advancement of lithium-rich cathode materials will likely catalyze the next significant progress in battery performance, safeguarding a sustainable future where clean energy is accessible and efficient for all.

Subject of Research: Lithium-rich layered oxides as cathode materials for lithium-ion batteries.
Article Title: Breakthrough Cathode Materials for Next-generation Lithium-ion Batteries
News Publication Date: October 2023
Web References: N/A
References: N/A
Image Credits: City University of Hong Kong

Keywords

Renewable energy, Energy storage, Lithium-ion batteries, Cathodes, Transition metals.

The project, directed by Professor Zheng Zongli from CityUHK’s Department of Biomedical Sciences, represents a significant step forward in targeting genetic diseases that have long been deemed resistant to treatment. Leveraging cutting-edge “DNA surgery” techniques, this team is set to embark on a three-year journey that aims to eliminate the root cause of these genetic disorders. The goal is to develop two innovative therapeutic medicines that will not only advance into clinical trials but also redefine patient care.

Central to this initiative is the concept of “one-and-done” therapies. These revolutionary treatments seek to provide lasting solutions for patients by effectively addressing the underlying genetic mutations responsible for various conditions. Traditional treatment methods often require ongoing management, which can be burdensome and costly for patients. By targeting the genetic source of the problem, CityUHK’s research team aspires to deliver safe and efficacious therapies that have the potential to significantly alter the treatment landscape for inherited diseases.

In June 2023, a pivotal moment marked the beginning of a new era in genetic medicine, with the U.S. Food and Drug Administration’s approval of Casgevy, the first-ever genome editing therapy. This breakthrough underscores a growing consensus that genome editing is not merely a theoretical concept but a practical solution to some of healthcare’s most vexing issues. The team at CityUHK is poised to build on this momentum, utilizing advanced genome editing tools to precisely target somatic mutations in patients’ DNA.

A salient feature of the proposed project is its integration of state-of-the-art delivery systems. Engineered lipid nanoparticles (eLNPs) have emerged as crucial vehicles for transporting genome editing tools into target cells. By enhancing the precision and efficiency of DNA delivery, these innovative systems are set to revolutionize how genetic therapies are administered. The CityUHK team is adept at employing these advanced delivery mechanisms in tandem with their proprietary high-fidelity nucleases, designed to minimize off-target effects and improve the overall safety profile of the treatment.

Gene therapy has traditionally faced challenges regarding durability, particularly in the treatment of autosomal dominant disorders. In these cases, a single faulty gene inherited from one parent can trigger the disease, often resulting in continuous production of harmful proteins that traditional therapies cannot effectively manage. The CityUHK project aims to address this significant gap by employing strategies that not only correct the genetic defect but also provide enduring solutions that alleviate the need for lifelong treatment.

A crucial aspect of this research involves the collaboration between multiple disciplines. The project’s team comprises experts in genetic engineering, biomedical sciences, and clinical research, all united by a common goal: to develop therapies that can fundamentally change how genetic diseases are approached. This multidisciplinary effort ensures that various challenges can be addressed from multiple angles, fostering innovation and enhancing the potential success of the therapeutic candidates.

The team’s emphasis on rigorous preclinical testing is testament to their commitment to safety and efficacy. Preliminary studies conducted in non-human primates have yielded promising results, demonstrating that the proposed genome editing approach can achieve industry-leading efficacy at lower dosages. This paves the way for future investigations aimed at translating these findings into human clinical trials, where the potential benefits for patients can truly be realized.

As the CityUHK team prepares for the next steps in their project, they are actively seeking partnerships with pharmaceutical companies to accelerate the development of their drug candidates. These partnerships could enhance the commercial viability of PL-100, aimed at treating a rare genetic disease of the liver, and PL-200, targeting cardiovascular diseases, which represent a significant burden on healthcare systems worldwide. Collaborative efforts between academia and industry are critical to navigating the complexities of drug development, ensuring that innovative therapies reach the patients who need them most.

The vision articulated by Professor Zheng is one of profound optimism. He believes that Hong Kong’s rich talent pool, robust research infrastructure, and supportive policies position the region to emerge as a leader in genomic medicine. The potential to transform patient outcomes through genome editing is immense, offering hope not only to local communities but potentially to patients worldwide struggling with genetic disorders.

Research initiatives like the one at CityUHK embody a broader paradigm shift in medicine — one that prioritizes solutions rooted in genetic understanding, aimed at curing diseases rather than merely managing their symptoms. As we stand on the cusp of a new frontier in healthcare, the importance of collaborative efforts, rigorous research, and innovative technologies cannot be overstated.

The time is ripe for breakthroughs in genomic medicine, driven by a confluence of scientific advancements and a commitment to patient-centered care. The work being undertaken at CityUHK is set to make a lasting impact not just within Hong Kong, but globally, heralding a new era of treatment possibilities for those afflicted by genetic conditions.

As we look to the future, the promise of genome editing shines brighter than ever. With dedicated teams committed to pushing the boundaries of what is possible, we can anticipate a landscape where genetic diseases are not simply endured but effectively treated, leading to healthier lives powered by the innovations of science.

Developing therapeutic candidates and navigating the path to clinical trials is a critical phase in transforming scientific discovery into tangible benefits for patients. With an eye toward expanding their research, the CityUHK team remains focused on achieving meaningful milestones that will bring their groundbreaking treatments from the laboratory to patients’ bedsides.

The next few years will be pivotal, as the CityUHK research team seeks to demonstrate the efficacy of their genome editing techniques in human trials, providing a potential lifeline to those who have been waiting for a cure. The synthesis of advanced genetic engineering tools, precise delivery systems, and thoughtful research design is paving the way for a future where genetic diseases can be confronted with renewed vigor.

As we await the outcomes of these trials, there is a palpable sense of excitement surrounding gene therapies. The horizon of medicine is shifting, and with ongoing support and collaboration, we can envision a time when genomic medicine is not just a dream but a reality for numerous patients across the globe.

Subject of Research: Genome editing for liver and cardiovascular genetic diseases
Article Title: CityUHK Team Pioneers New Era of Genome Editing in Treatment of Genetic Disorders
News Publication Date: [Not Specified]
Web References: [Not Specified]
References: [Not Specified]
Image Credits: City University of Hong Kong

Keywords
Genome editing, Genetic engineering, Targeted genome editing, CRISPRs, DNA, Mutation, Genetic disorders, Gene targeting, Heart disease, Liver.